Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Abiomed, Inc.

Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
First Patient in Japan Treated with Impella 5.5 with SmartAssist
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present at Upcoming Investor Conferences
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present at Upcoming Investor Conferences
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.